Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1995 Jan;114(2):297–302. doi: 10.1111/j.1476-5381.1995.tb13226.x

Selectivity of [125I]-PD151242 for human, rat and porcine endothelin ETA receptors in the heart.

M G Peter 1, A P Davenport 1
PMCID: PMC1510233  PMID: 7881728

Abstract

1. Endothelin-1 binds with high affinity to heart where it acts as a potent positive inotropic agent. Our aim was to characterize the labelled and unlabelled ETA-selective antagonist PD151242 in heart tissues derived from man, rat and pigs by use of radioligand binding techniques. 2. Binding of [125I]-PD151242 to sections of human left ventricle was time-dependent and reached equilibrium after 120 min at 23 degrees C with an association rate constant of 0.0235 min-1 nM-1. The binding was reversible at 23 degrees C with a dissociation rate constant of 0.00144 min-1. 3. Saturation binding assays with [125I]-PD151242 revealed a single population of high affinity ET receptors in human left ventricle (KD = 1.07 +/- 0.08 nM; Bmax = 29.8 +/- 4.2 fmol mg-1 protein), porcine left ventricle (KD = 1.92 +/- 0.27 nM; Bmax = 493 +/- 248 fmol mg-1 protein), and rat heart (KD = 0.64 +/- 0.08 nM; Bmax = 82.34.7 fmol mg-1 protein). 4. Unlabelled PD151242 competed with specific [125I]-ET-1 binding to human left ventricle tissue in a biphasic manner with high affinity binding to the ETA-site (KD = 7.21 +/- 2.83 nM) and lower affinity for the ETB-subtype (KD = 104 +/- 23 microM), indicating a greater than 10000 fold selectivity to the high affinity site. 5. The ETA-selective ligand FR139317 competed for [125I]-PD151242 binding in human left ventricle with nanomolar affinity (KD = 0.37 +/- 0.10 nM), whereas the ETB-selective compound, BQ3020, competed with only micromolar affinity (KD = 1.5 +/- 0.26 microM).(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
297

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arai H., Hori S., Aramori I., Ohkubo H., Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature. 1990 Dec 20;348(6303):730–732. doi: 10.1038/348730a0. [DOI] [PubMed] [Google Scholar]
  2. Bax W. A., Bruinvels A. T., van Suylen R. J., Saxena P. R., Hoyer D. Endothelin receptors in the human coronary artery, ventricle and atrium. A quantitative autoradiographic analysis. Naunyn Schmiedebergs Arch Pharmacol. 1993 Oct;348(4):403–410. doi: 10.1007/BF00171340. [DOI] [PubMed] [Google Scholar]
  3. Bolger G. T., Liard F., Krogsrud R., Thibeault D., Jaramillo J. Tissue specificity of endothelin binding sites. J Cardiovasc Pharmacol. 1990 Sep;16(3):367–375. doi: 10.1097/00005344-199009000-00004. [DOI] [PubMed] [Google Scholar]
  4. Davenport A. P., Kuc R. E., Hoskins S. L., Karet F. E., Fitzgerald F. [125I]-PD151242: a selective ligand for endothelin ETA receptors in human kidney which localizes to renal vasculature. Br J Pharmacol. 1994 Dec;113(4):1303–1310. doi: 10.1111/j.1476-5381.1994.tb17140.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Davenport A. P., Morton A. J., Brown M. J. Localization of endothelin-1 (ET-1), ET-2, and ET-3, mouse VIC, and sarafotoxin S6b binding sites in mammalian heart and kidney. J Cardiovasc Pharmacol. 1991;17 (Suppl 7):S152–S155. doi: 10.1097/00005344-199100177-00042. [DOI] [PubMed] [Google Scholar]
  6. Davenport A. P., Nunez D. J., Hall J. A., Kaumann A. J., Brown M. J. Autoradiographical localization of binding sites for porcine [125I]endothelin-1 in humans, pigs, and rats: functional relevance in humans. J Cardiovasc Pharmacol. 1989;13 (Suppl 5):S166–S170. doi: 10.1097/00005344-198900135-00045. [DOI] [PubMed] [Google Scholar]
  7. DeBlasi A., O'Reilly K., Motulsky H. J. Calculating receptor number from binding experiments using same compound as radioligand and competitor. Trends Pharmacol Sci. 1989 Jun;10(6):227–229. doi: 10.1016/0165-6147(89)90266-6. [DOI] [PubMed] [Google Scholar]
  8. Gu X. H., Casley D. J., Nayler W. G. Characterization of [125I]endothelin-1 binding sites in rat cardiac membrane fragments. J Cardiovasc Pharmacol. 1989;13 (Suppl 5):S171–S173. doi: 10.1097/00005344-198900135-00046. [DOI] [PubMed] [Google Scholar]
  9. Hemsén A., Franco-Cereceda A., Matran R., Rudehill A., Lundberg J. M. Occurrence, specific binding sites and functional effects of endothelin in human cardiopulmonary tissue. Eur J Pharmacol. 1990 Dec 4;191(3):319–328. doi: 10.1016/0014-2999(90)94164-s. [DOI] [PubMed] [Google Scholar]
  10. Ihara M., Noguchi K., Saeki T., Fukuroda T., Tsuchida S., Kimura S., Fukami T., Ishikawa K., Nishikibe M., Yano M. Biological profiles of highly potent novel endothelin antagonists selective for the ETA receptor. Life Sci. 1992;50(4):247–255. doi: 10.1016/0024-3205(92)90331-i. [DOI] [PubMed] [Google Scholar]
  11. Ito H., Hirata Y., Adachi S., Tanaka M., Tsujino M., Koike A., Nogami A., Murumo F., Hiroe M. Endothelin-1 is an autocrine/paracrine factor in the mechanism of angiotensin II-induced hypertrophy in cultured rat cardiomyocytes. J Clin Invest. 1993 Jul;92(1):398–403. doi: 10.1172/JCI116579. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Ito H., Hiroe M., Hirata Y., Fujisaki H., Adachi S., Akimoto H., Ohta Y., Marumo F. Endothelin ETA receptor antagonist blocks cardiac hypertrophy provoked by hemodynamic overload. Circulation. 1994 May;89(5):2198–2203. doi: 10.1161/01.cir.89.5.2198. [DOI] [PubMed] [Google Scholar]
  13. Karne S., Jayawickreme C. K., Lerner M. R. Cloning and characterization of an endothelin-3 specific receptor (ETC receptor) from Xenopus laevis dermal melanophores. J Biol Chem. 1993 Sep 5;268(25):19126–19133. [PubMed] [Google Scholar]
  14. Kumar C. S., Nuthulaganti P., Pullen M., Nambi P. Novel endothelin receptors in the follicular membranes of Xenopus laevis oocytes mediate calcium responses by signal transduction through gap junctions. Mol Pharmacol. 1993 Jul;44(1):153–157. [PubMed] [Google Scholar]
  15. Li K., Stewart D. J., Rouleau J. L. Myocardial contractile actions of endothelin-1 in rat and rabbit papillary muscles. Role of endocardial endothelium. Circ Res. 1991 Aug;69(2):301–312. doi: 10.1161/01.res.69.2.301. [DOI] [PubMed] [Google Scholar]
  16. Maguire J. J., Kuc R. E., O'Reilly G., Davenport A. P. Vasoconstrictor endothelin receptors characterized in human renal artery and vein in vitro. Br J Pharmacol. 1994 Sep;113(1):49–54. doi: 10.1111/j.1476-5381.1994.tb16172.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Masaki T. Tissue specificity of the endothelin-induced responses. J Cardiovasc Pharmacol. 1991;17 (Suppl 7):S1–S4. doi: 10.1097/00005344-199100177-00002. [DOI] [PubMed] [Google Scholar]
  18. Matsuyama K., Yasue H., Okumura K., Saito Y., Nakao K., Shirakami G., Imura H. Increased plasma level of endothelin-1-like immunoreactivity during coronary spasm in patients with coronary spastic angina. Am J Cardiol. 1991 Oct 15;68(10):991–995. doi: 10.1016/0002-9149(91)90484-3. [DOI] [PubMed] [Google Scholar]
  19. McPherson G. A. A practical computer-based approach to the analysis of radioligand binding experiments. Comput Programs Biomed. 1983 Aug-Oct;17(1-2):107–113. doi: 10.1016/0010-468x(83)90031-4. [DOI] [PubMed] [Google Scholar]
  20. Molenaar P., Kuc R. E., Davenport A. P. Characterization of two new ETB selective radioligands, [125I]-BQ3020 and [125I]-[Ala1,3,11,15]ET-1 in human heart. Br J Pharmacol. 1992 Nov;107(3):637–639. doi: 10.1111/j.1476-5381.1992.tb14498.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Molenaar P., O'Reilly G., Sharkey A., Kuc R. E., Harding D. P., Plumpton C., Gresham G. A., Davenport A. P. Characterization and localization of endothelin receptor subtypes in the human atrioventricular conducting system and myocardium. Circ Res. 1993 Mar;72(3):526–538. doi: 10.1161/01.res.72.3.526. [DOI] [PubMed] [Google Scholar]
  22. Moravec C. S., Reynolds E. E., Stewart R. W., Bond M. Endothelin is a positive inotropic agent in human and rat heart in vitro. Biochem Biophys Res Commun. 1989 Feb 28;159(1):14–18. doi: 10.1016/0006-291x(89)92397-8. [DOI] [PubMed] [Google Scholar]
  23. Munson P. J., Rodbard D. Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem. 1980 Sep 1;107(1):220–239. doi: 10.1016/0003-2697(80)90515-1. [DOI] [PubMed] [Google Scholar]
  24. Nambi P., Pullen M., Spielman W. Species differences in the binding characteristics of [125I]IRL-1620, a potent agonist specific for endothelin-B receptors. J Pharmacol Exp Ther. 1994 Jan;268(1):202–207. [PubMed] [Google Scholar]
  25. Sakamoto A., Yanagisawa M., Sakurai T., Takuwa Y., Yanagisawa H., Masaki T. Cloning and functional expression of human cDNA for the ETB endothelin receptor. Biochem Biophys Res Commun. 1991 Jul 31;178(2):656–663. doi: 10.1016/0006-291x(91)90158-4. [DOI] [PubMed] [Google Scholar]
  26. Sogabe K., Nirei H., Shoubo M., Nomoto A., Ao S., Notsu Y., Ono T. Pharmacological profile of FR139317, a novel, potent endothelin ETA receptor antagonist. J Pharmacol Exp Ther. 1993 Mar;264(3):1040–1046. [PubMed] [Google Scholar]
  27. Sokolovsky M., Ambar I., Galron R. A novel subtype of endothelin receptors. J Biol Chem. 1992 Oct 15;267(29):20551–20554. [PubMed] [Google Scholar]
  28. Suzuki T., Kumazaki T., Mitsui Y. Endothelin-1 is produced and secreted by neonatal rat cardiac myocytes in vitro. Biochem Biophys Res Commun. 1993 Mar 31;191(3):823–830. doi: 10.1006/bbrc.1993.1291. [DOI] [PubMed] [Google Scholar]
  29. Takanashi M., Endoh M. Characterization of positive inotropic effect of endothelin on mammalian ventricular myocardium. Am J Physiol. 1991 Sep;261(3 Pt 2):H611–H619. doi: 10.1152/ajpheart.1991.261.3.H611. [DOI] [PubMed] [Google Scholar]
  30. Takayanagi R., Hashiguchi T., Ohashi M., Nawata H. Regional distribution of endothelin receptor in porcine cardiovascular tissues. Regul Pept. 1990 Feb 4;27(2):247–255. doi: 10.1016/0167-0115(90)90043-v. [DOI] [PubMed] [Google Scholar]
  31. Takayanagi R., Ohnaka K., Takasaki C., Ohashi M., Nawata H. Multiple subtypes of endothelin receptors in human and porcine tissues: characterization by ligand binding, affinity labeling, and regional distribution. J Cardiovasc Pharmacol. 1991;17 (Suppl 7):S127–S130. doi: 10.1097/00005344-199100177-00034. [DOI] [PubMed] [Google Scholar]
  32. Tønnessen T., Naess P. A., Kirkebøen K. A., Offstad J., Ilebekk A., Christensen G. Release of endothelin from the porcine heart after short term coronary artery occlusion. Cardiovasc Res. 1993 Aug;27(8):1482–1485. doi: 10.1093/cvr/27.8.1482. [DOI] [PubMed] [Google Scholar]
  33. Watanabe T., Suzuki N., Shimamoto N., Fujino M., Imada A. Contribution of endogenous endothelin to the extension of myocardial infarct size in rats. Circ Res. 1991 Aug;69(2):370–377. doi: 10.1161/01.res.69.2.370. [DOI] [PubMed] [Google Scholar]
  34. Wharton J., Rutherford R. A., Gordon L., Moscoso G., Schiemberg I., Gaer J. A., Taylor K. M., Polak J. M. Localization of endothelin binding sites and endothelin-like immunoreactivity in human fetal heart. J Cardiovasc Pharmacol. 1991;17 (Suppl 7):S378–S384. doi: 10.1097/00005344-199100177-00107. [DOI] [PubMed] [Google Scholar]
  35. Yasuda M., Kohno M., Tahara A., Itagane H., Toda I., Akioka K., Teragaki M., Oku H., Takeuchi K., Takeda T. Circulating immunoreactive endothelin in ischemic heart disease. Am Heart J. 1990 Apr;119(4):801–806. doi: 10.1016/s0002-8703(05)80315-1. [DOI] [PubMed] [Google Scholar]
  36. Zerkowski H. R., Broede A., Kunde K., Hillemann S., Schäfer E., Vogelsang M., Michel M. C., Brodde O. E. Comparison of the positive inotropic effects of serotonin, histamine, angiotensin II, endothelin and isoprenaline in the isolated human right atrium. Naunyn Schmiedebergs Arch Pharmacol. 1993 Apr;347(4):347–352. doi: 10.1007/BF00165383. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES